Hc Advisors, LLC 89bio, Inc. Transaction History

Hc Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 07, 2021	SELL	$20.22 - $26.73 $218,901 - $289,378	-10,826 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$23.16 - $28.08 $128,144 - $155,366	-5,533 Reduced 33.82%	10,826 $264,000
Q3 2020 Nov 04, 2020	BUY	$24.34 - $38.82 $72,022 - $114,868	2,959 Added 22.08%	16,359 $420,000
Q2 2020 Aug 12, 2020	BUY	$19.93 - $31.2 $267,062 - $418,080	13,400 New	13,400 $267,000

173

125M

78.7K

979K

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $388M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Hc Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Hc Advisors, LLC with notifications on news.